A new endotoxin adsorption device in Gram-negative sepsis: Use of immobilized albumin with the MATISSE® adsorber

Transfusion and Apheresis Science

Volumn 29, Issue 1, 2003, Pages 93-98

  Staubach, Karl Hermann ^a   Boehme, Marc ^b   Zimmermann, Michael ^b   Otto, Veit ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Fresenius HemoCare Adsorber T   (Germany)

Author keywords

Albumin; Apheresis; Endotoxin removal; Sepsis treatment

Indexed keywords

ALBUMIN; BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN;

APHERESIS; CLINICAL TRIAL; CONFERENCE PAPER; DEVICE; ELIMINATION REACTION; ENDOTOXEMIA; GRAM NEGATIVE BACTERIUM; HEMOPERFUSION; HUMAN; IMMUNOADSORPTION; INSULIN BLOOD LEVEL; MACHINE; METHODOLOGY; PERITONITIS; PROTEIN IMMOBILIZATION; SAFETY; SEPSIS; THROMBOCYTE COUNT;

EID: 0038499232     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(03)00100-9     Document Type: Conference Paper

References (16)

1. Centre for Disease Control: Increase in National Hospital Discharge Survey rates for Septicemia - United States, 1979-1987. MMWR 1990;39:31-4.
2. Sands K.E.et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 278:1997;234-240.
3. Angus D.C.et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:2001;1303-1310.
4. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 26:2000;64-74.
5. Morrison D.C., Ulevitch R.J. The effects of bacterial endotoxins on host mediation systems. Am. J. Pathol. 93:1978;526-617.
6. Galanos C., Freudenberg M.A., Katschinski T., Salomao R., Mossmann H., Kumazawa Y. Tumor necrosis factor and host response to endotoxin. Ryan J.L., Morrison D.C. Immunopharmacology and pathophysiology. 1992;75-102 CRC Press, Boca Raton.
7. Alexander A., Rietschel E.T. Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res. 7(3):2001;167-202.
8. Greenman R.L., Schein R.M., Martin M.A., Wenzel R.P., McIntyre N.R., Emmanuel G.et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. J. Am. Assess. 266:1991;1097-1102.
9. Ziegler E.J., Fischer C.J., Sprung C.L., Straube R.C., Sadoff J.C., Foulke G.E.et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N. Engl. J. Med. 324:1991;429-436.
10. Marra M.N., Thornton M.B., Snable J.L., Wilde C.G., Scott R.W. Endotoxin-binding and -neutralising properties of recombinant bactericidal/permeability- increasing protein and monoclonal antibodies HA-1A and E5. Crit. Care Med. 22:1994;559-565.
11. Aoki H., Kodama M., Tani T., Hanasawa K. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilised fibre. Am. J. Surg. 167:1994;412-417.
12. Uriu K., Osajima A., Kamochi M., Watanabe H., Aibara K., Kaizu K. The severity of hyperdynamic circulation may predict the effects of direct hemoperfusion with the adsorbent column using polymyxin B-immobilized fiber in patients with Gram-negative septic shock. Ther. Apher. 5(1):2001;25-30.
13. Nakamura T., Ebihara I., Shimada N., Susuki S., Ushiyama C., Shoji H. Effects of hemoperfusion with polymyxin B-immobilized fibre on serum neopterin and soluble interleukin-2 receptor concentrations in patients with septic shock. J. Infect. 37:1998;241-247.
14. Tani T., Hanasawa K., Endo Y., Yoshioka T., Kodama M., Kaneko M. Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilised column. Artif. Organs. 22(12):1998;1038-1044.
15. Zimmermann M., Busch K., Kuhn S., Zeppezauer M. Endotoxin adsorbent based on immobilised human serum albumin. Clin. Chem. Lab. Med. 37(3):1999;373-379.
16. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Crit Care 1992;20:6-16.